Home > Dermatology > AAD 2021 > COVID-19: What Dermatologists Need to Know > Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on

Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on

Presented By
Prof. April W. Armstrong, University of Southern California, USA
Conference
AAD VMX 2021
In the management of patients with chronic dermatologic diseases during the pandemic, many questions have arisen. Guidance is provided by various experts. “Our discussion about biologics needs to be contextualised with regard to which phase of COVID-19 the patient might be in,” explained Prof. April W. Armstrong (University of Southern California, USA) [1,2]. She started by looking at various clinical trial results in a meta-analysis for respiratory tract infection (RTI). Concerning TNF inhibition for psoriasis and hidradenitis suppurativa (HS), RTI rates were comparable between the various study drugs and placebo [2,3]. Moreover, RTI data in psoriasis trials with IL-17 inhibitors was not different between IL-17 inhibitor treatment and placebo in most cases. Furthermore, no increased risk of RTI was found for IL-23 inhibitors in phase 3 trials [1]. Even the likelihood of viral infections was not elevated either with IL-23 or IL-12/23 inhibition, the latter...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on